Assistant Professor and Fellowship Director,
Department of Urology, Division of Surgery
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Dual/Joint Appointment

Assistant Professor, Department of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

HONORS AND AWARDS

-Gold Medal Performance, University of Bombay, Medical Examination, 1991
-Distinctions in Forensic Medicine and Medical Jurisprudence, Pharmacology, Microbiology, Biochemistry and Preventive and Social Medicine, 1991
-Manorama Vijayrat Hazarat Prize for Highest Cumulative Score, 1991
-Shamdasani Foundation Scholarship for Standing First in University, 1991
-Seth Khimchand Amulakh Prize for Excellence in Pharmacology, 1991
-Dr. L. H. Hiranandani Scholarship in Otorhinolaryngology, 1992
-Best Paper, 8th Annual Resident Paper Presentation, West Virginia University, 1997
-Pfizer ‘Scholars in Urology’ National Award, 1999
-First Prize, American College of Surgeons regional research meeting, May 1999
-First Prize, Zimmerman Paper Competition, West Virginia University, April 1999
-Second prize, Pittsburgh Urological Meeting, University of Pittsburgh, April 1999
-First Prize, American College of Surgeons regional research meeting, May 2000
-Best Published Papers in ‘Urology’, awarded at AUA annual meeting, May 2000
-Outstanding Laparoendoscopist, Society of Laparoendoscopic Surgeons, 2001
-Scholar in Training Award, American Association for Cancer Research, 2002
-Bladder SPORE Developmental Research Program Award, 2003
-Faculty Award, AACR Workshop: Methods in Clinical Cancer Research, 2004
-Listed in ‘Who’s Who in America’, 60th Edition, 2005

PUBLICATIONS

a. Articles in Peer-Reviewed Journals (* = Senior/Corresponding Author)

-Kamat AM, Lamm DL: Chemoprevention of urologic cancer. J Urol 161(6): 1748-1760, 1999.
-Kamat AM, DeHaven JI, Lamm DL: Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1): 56-61, 1999.
-Kamat AM, Lamm DL: Role of BCG in treatment of superficial bladder cancer. Indian Journal of Urology 16(1): 1-9, 1999.
-Kamat AM, Hrabovsky E: Imperforate anus: an unusual presentation of a common disease. W V Med J 95(6): 305-306, 1999.
-Kamat AM, Lamm DL: Intravesical therapy for superficial bladder cancer. Inf Urol 12(2): 37-45, 1999.
-Kamat AM, Lamm DL: Intravesical therapy for bladder cancer. Urology 55(2): 161-168, 2000.
-Kamat AM, Lamm DL: Current trends in intravesical therapy for bladder cancer. Contemp Urol 12(8): 64-88, 2000.
-Kamat AM, Lamm DL: Diet and nutrition in urologic cancer. W V Med J 96(3): 449-454, 2000.
-Kamat A, York T, DeBord J: Anastomotic fistula after ileal loop urinary diversion presenting as persistent urethral drainage. J Urol 165(3): 906-907, 2001.
-Kamat AM, Lamm DL: Immunotherapy for bladder cancer. Curr Urol Rep 2(1): 62-69, 2001.
-Kamat AM, Lamm DL: Chemoprevention of bladder cancer. Urol Clin N Am 29(1): 1-12, 2002.
-Karashima T, Sweeney P, Kamat A, Huang S, Kim SJ, Bar-Eli M, McConkey DJ, Dinney CP: Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 9(7): 2786-2797, 2003.
-Kamat AM, Dinney CPN: Molecular aspects of metastases in bladder cancer. Urol Integ Invest 8(2): 180-189, 2003.
-Kamat AM: Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6): 799-808, 2003.
-Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Guitreau DP, Pisters LL: Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5): 1868-1871, 2003.
-Kamat AM, Babaian KR, Cheung MR, Naya Y, Huang S, Kuban D, Babaian RJ: Identification of factors predicting for response to adjuvant radiation therapy for positive margin after radical prostatectomy. J Urol 170(5): 1860-1863, 2003.
-Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL: Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5): 1856-1859, 2003.
-Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL: Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63(1): 46-50, 2004.
-Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3): 457-460, 2004.
-Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CPN, McConkey DJ: The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3): 279-290, 2004.
-Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA: Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5): 1886-1887, 2004.
-Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL: Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7): 939-944, 2004.
-Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL: Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63(6): 1132-1137, 2004.
-Herring JC, Kamat AM*: Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6): 1047-1056, 2004.
-Kassouf W, Kamat AM*: Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6): 1037-1046, 2004.
-Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B: Focus on bladder cancer. Cancer Cell 6(2): 111-116, 2004.
-Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL: Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1): 101–104, 2005.
-Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA: Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-19, 2005.
-Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D: Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 61(4):993-1002, 2005
-Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: Impact of delayed diagnosis. Urol Oncol. 23(2):130-1, 2005
-Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve-sparing radical prostatectomy. J Urol, 174(4):1262-5, 2005.
-Shapiro A, Vakar F, Kamat AM*. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis. Urol Oncol. 23(5): 352-3, 2005
-Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology, 66(2):327-31, 2005
-Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 63(1):134-40, 2005.
-Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF(121)/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia. 7(10):912-20, 2005.
-Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-2190, 2005.
-Kamat AM, Nelkin GM: Atorvastatin: A potential chemopreventive agent in bladder cancer. Urology 66(6):1209-12, 2005.
-Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM*: Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl) methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Research. 66(1):412-8, 2006.
-Kamat AM*, Gee JR, Dinney CPN, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL: The case for early cystectomy in treatment of non-muscle-invasive micropapillary bladder carcinoma. J Urol. 175(3):881-5, 2006
-Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): The impact of aggressive surgical resection on patient outcome. J Urol, 175(3):864-9, 2006
-Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology. 67(3):518-23, 2006.
-Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 67(3):466-71, 2006.
-Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanchez-Ortiz RF, Pisters LL: Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology, 67 (4):769-73, 2006.
-Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol., 175(6):2058-62, 2006.
-Rosser CJ, Kamat AM*, Pendleton J, Robinson T, Pisters LL, Swanson DA, Babaian RJ: Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer, 107(1): 54-9, 2006.
-Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA.: Influence of Obesity on Biochemical and Clinical Failure after External-Beam Radiotherapy for Localized Prostate Cancer. Cancer, 2006 (in press).
-Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM*: Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol, 176 (1):53-7, 2006.
-Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM*: Relevance of Extracapsular Extension of Pelvic Nodal Metastasis in Patients With Bladder Cancer Treated in the Contemporary Era. Cancer, 2006 (in press).
-Dhanani N, Kamat AM*: Treatment of bladder cancer in cardiac transplant patients. Int Urology, 2006 (in press)
-Busby JE, Kamat AM*: Chemoprevention of Bladder Cancer. J Urol, 2006 (in press)
-Kassouf W, Highshaw RA, Nelkin GM, Dinney CPN, Kamat AM*: Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol, 2006 (in press)
-Papageorgiou A, Kamat AM, Benedict W, Dinney CPN, McConkey DJ: Combination therapy with interferon-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder tumor xenografts. Mol Cancer Ther, 2006 (in press)

b. Invited Articles

-Kamat AM, Lamm DL: Current trends in intravesical therapy for bladder cancer. Contemp Urol 12(8): 64-88, 2000.
-Kamat AM, Lamm DL: Diet and nutrition in urologic cancer. W V Med J 96(3): 449-454, 2000.
-Kamat AM, Dinney CPN: Molecular aspects of metastases in bladder cancer. Urol Integ Invest 8(2): 180-189, 2003.
-Kamat AM: Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6): 799-808, 2003.
-Herring JC, Kamat AM*: Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6): 1047-1056, 2004.
-Kassouf W, Kamat AM*: Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6): 1037-1046, 2004.
-Metwalli A, Kamat AM*: Controversies and optimal management of T1G3 bladder cancer. Expert Rev Anticancer Ther 2006 (in press).
-Brassell SA, Kamat AM*: Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder. J Natl Compr Canc Netw, 2006 (in press)

c. Editorials:
-Kamat AM: Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care? Am J Clin Onc Rev 2(11): 624-637, 2003.
-Kamat AM: Outcome of penile cancer in circumcised men. J Urol. 175(2): 561, 2006.
-Kamat AM, Dinney CP: Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Nat Clin Pract Urol 2006 (in press)

d. Other Articles
N/A

e. Abstracts

-Kamat AM, DeHaven JI, Riggs DR, Pathak VK, Hu WS, Lamm DL: Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. J Urol 161(4S): 119, 1999.
-Kamat AM, DeHaven JI, Lamm DL: Cytotoxic effect of Nerium oleander extract on bladder cancer cells. J Urol 161(4S): 115, 1999.
-Kamat AM, DeHaven JI, Lamm DL: Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. ASCO Program Proceedings, No. 1319, 1999.
-DeHaven JI, Anderson MI, Kamat AM, Riggs DR, Hogan TF, Lamm DL: Combined and sequential paclitaxel-based chemosensitivity in renal cell adenocarcinoma cell lines. ASCO Program Proceedings, No. 1296, 1999.
-Kamat AM, Riggs DR, Lamm DL: Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model (MBT2). J Urol 163(4S): 118, 2000.
-Kamat AM, Karashima T, Davis DW, Dinney CPN, McConkey DJ: The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. J Urol 169(4S): 495, 2003.
-Kamat AM, Kedar D, Bermejo C, Davis D, Radinsky R, Elliott W, Bar-Eli M, McConkey D, Dinney C: CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. J Urol 169(4S): 504, 2003.
-Bermejo C, Sanchez-Ortiz R, Kamat AM, Daliani D, Pettaway C: Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile carcinoma. J Urol 169(4S): 683, 2003.
-Bermejo C, Dinney C, Kamat A, Kedar D, Mirabilis R, McConkey D, Elliott W, Bar-Eli M: Downstream signaling pathways and antiangiogenic effects of the pan-erbb tyrosine kinase inhibitor CI-1033 in a human bladder cancer cell line. J Urol 169(4S): 730, 2003.
-Kamat AM, Riggs D, Lamm DL: Anti-tumor activity of common antibiotics against superficial bladder cancer. J Urol 169 (4S): 988, 2003.
-Kamat AM, Rosser CJ, Levy LB, Chichakli R, Pisters LL: Fluctuation of > 1.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure. J Urol 169(4S): 1719, 2003.
-Canfield SE, Kamat AM, Sanchez-Ortiz RF, Swanson DA, Wood CG: Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): predictive factors for survival. J Urol 171(4S): 1787, 2004.
-Khanna A, Fernandez R, Payne L, Zhang H, Bekele B, Kamat A, Caraway N, Katz RL: Telomere length is more highly associated with urothelial cancer in urinary tract cytology specimens than DNA ploidy and bladder recurrence FISH test. American Society of Cytopathology Annual Scientific Meeting, 2004.
-Highshaw R, Nelkin G, Matin S, Kamat AM. Atorvastatin: Potential For Use as an Anti-Tumor Agent in Bladder Cancer. J Urol 173(4S): 161, 2005.
-Highshaw R, Dinney C, Bermejo C, Nelkin G, Kamat AM. Isolation and Characterization of metastatic variants obtained by orthotopic recycling of the papillary human transitional cell carcinoma (rt4) cell line. J Urol 173(4S): 159, 2005.
-Jacobsohn K, Kamat AM, Troncoso P, Shen Y, Wen S, Babaian R. Validation of selection criteria used in predicting extraprostatic cancer extension in patients undergoing nerve-sparing radical prostatectomy. J Urol 173(4S): 186, 2005..
-Kamat AM, Gee J, Dinney C, Grossman H, Swanson D, Millikan R, Robinson T, Pisters L. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. J Urol 173(4S): 247, 2005.
-Kamat AM, Gee J, Grossman H, Dinney C, Siefer-Radtke A, Millikan R, Swanson D, Robinson T, Pisters L. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. J Urol 173(4S): 302, 2005.
-Kassouf W, Leibovici D, Zhou X, Dinney C, Grossman H, Siefker-Radtke A, Pisters L, Swanson D, Kamat AM. Significance of lymph node positive disease in patients treated with neoadjuvant chemotherapy: Is adjuvant chemotherapy beneficial? J Urol 173(4S): 358, 2005.
-Kassouf W, Leibovici D, Dinney C, Grossman H, Kamat AM. Validation of the concept of lymph node density in a contemporary series of patients. J Urol 173(4S): 358, 2005.
-Kassouf W, Safe S, Abdelrahim M, Chintharlapalli S, Nelkin G, Kamat AM. Activity of novel agonists of peroxisome proliferator-activated receptor gamma (ppar-gamma) against human transitional cell tumors. J Urol 173(4S): 211, 2005.
-Kassouf W, Highshaw R, Nelkin G, Dinney C, Kamat AM. Vitamin C and K3 sensitize human transitional cell tumors to gemcitabine. J Urol 173(4S): 207, 2005.
-Leibovici D, Kassouf W, Kamat AM, Pisters L, Pettaway C, Dinney C. Transurethral tumor resection versus partial cystecomy for bladder preservation for muscle invasive cancer. J Urol 173(4S): 303, 2005.
-Kamat AM, Rosser C, Wen S, Cheung R, Lee A, Putman S, Pisters L. Body Mass Index Does Not Affect Outcome For Men Undergoing External-Beam -Radiotherapy For Localized Prostate Cancer. J Urol 173(4S): 280, 2005.
-Spiess P, Evans J, Kamat AM, Wood C, Pettaway C, Dinney C, Pisters L. Chylous Ascites after Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. J Urol 173(4S): 197, 2005.
-Spiess PE, Kassouf W, Brown GA, Kamat AM, Gomez JA, Evans J, Pisters, LL: M. D. Anderson experience in the clinical management of growing teratoma syndrome. J Urol 175: 4(S):448, 2006.
-Spiess PE, Brown GA, Pettaway CA, Gomez JA, Evans J, Kassouf W, Black PC, Kamat AM, Pisters LL: Malignant transformation of testicular teratoma: a chemoresistant phenotype. J Urol 175: 4(S):455, 2006.
-Brown GA, Spiess PE, Bassett RL, Grossman HB, Dinney CPN, Kamat AM: Contemporary management of primary carcinomas of the female urethra. J Urol 175: 4(S):462, 2006.
-Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CPN, Kamat AM: Management of primary carcinomas of the male urethra. J Urol 175: 4(S):463, 2006.
-Spiess PE, Brown GA, Liu P, Evans J, Kamat AM, Pisters LL: Recurrence pattern and proposed surveillance protocol in patients following post-chemotherapy retroperitoneal lymph note dissection. J Urol 175: 4(S):595, 2006.
-Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney CPN, Kamat AM: Natural history of bladder cancer in patients with P0 disease at radical cystectomy. J Urol 175: 4(S):1233, 2006.
-Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CPN, Millikan RE: Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol 175: 4(S):1240, 2006.
Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney, CPN, -Kamat AM: A comparison of performance of TNM staging versus lymph node density in risk stratification of patients undergoing cystectomy for urothelial carcinoma. J Urol 175: 4(S):1251, 2006.

f. Book Chapters

Kamat AM: Laboratory investigation in urology. In: Urology for Primary Care Physicians (eds, Nseyo UO, Weinman E, Lamm DL). WB Saunders, pp. 23-31, 1999.
Kamat AM, Nseyo UO: Dysuria. In: Five Minute Urology Consult (ed, Gomella LG). Philadelphia: Lippincott, pp. 28-29, 2000.

g. Books (edited and written)

h. Letters to the Editor

i. Manuals, Teaching Aids, Other Publications

BCG Immunotherapy: Bladder Cancer and Beyond. CME Supplement to ‘Renal & Urology News’, October 2004.
Prostate Cancer Guidelines, HealthGate, Burlington, MA, 2005
Bladder Cancer Options – State of the Art Patient Care, Volume 1 and 2, 2005
Presentations at National or International Conferences

“Cytotoxic effect of Nerium oleander extract on bladder cancer cells,” Society for Basic Urologic Research (SBUR), Prouts Neck, ME, 1998.
“Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model,” American Urological Association Annual Meeting, Dallas, TX, May 1999.
“Cytotoxic effect of Nerium oleander extract on bladder cancer cells,” American Urological Association Annual Meeting, Dallas, TX, May 1999.
“Cytotoxic effect of Nerium oleander extract on bladder cancer cells,” American Society of Clinical Oncology Annual Meeting, Atlanta, GA, May 1999.
“CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis,” Society for Urologic Oncology, Bethesda, MD, December 2002.
“The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine,” American Association for Cancer Research Annual Meeting, San Francisco, CA, April 2002.
“Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model,” American Association for Cancer Research Annual Meeting, San Francisco, CA, April 2002.
“Antitumor activity of common antibiotics against superficial bladder cancer,” American
Urological Association Annual Meeting, Chicago, IL, April 2003.
“Fluctuation of greater than 1.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure,” American Urological Association Annual Meeting, Chicago, IL, April 2003.
“The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder,” American Urological Association Annual Meeting, San Antonio, TX, May 2005.
“Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients,” American Urological Association Annual Meeting, San Antonio, TX, May 2005.
“Smac Mimetics: Application in Bladder Cancer Therapy,” NCI SPORE Meeting, Baltimore, MD, July 2006.

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Member, Harris County Medical Society
Member, Texas Medical Association
Member, Southwest Oncology Group (SWOG)
Member, South Central Section of the American Urological Association
Member, American Association of Cancer Research
Member, Society of Urologic Oncology
Member, American Urological Association
Member, American Medical Association

VOLUNTEER/ADVOCACY ACTIVITIES

Local/State

Bladder Cancer Support Group, MD Anderson Cancer Center

National and International

Member, Scientific Advisory Panel
Bladder Cancer Advocacy Network, Bethesda, MD

Member, Scientific Advisory Board:
Bladder Cancer WebCafe, patient's information, resource and support site; The Netherlands